R2 Technologies is a world leader in CryoAesthetic™ medical devices. Headquartered in Silicon Valley, R2 focuses on the development and commercialization of groundbreaking technologies for aesthetic providers and consumers. Based on the licensed exclusive intellectual property from Massachusetts General Hospital and Blossom Innovations to modulate melanin production, R2 Technologies was founded in 2014 by Pansend Life Sciences and Blossom Innovations. R2 has also secured investment from its strategic partner, Huadong Medicine. Working with these partners, in conjunction with our scientific founders, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 Technologies is launching the Glacial® brands into the market in 2021.